Detalles de la búsqueda
1.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet
; 395(10240): 1845-1854, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32450106
2.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
3.
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Emerg Microbes Infect
; 13(1): 2281355, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933089
4.
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Lancet Infect Dis
; 23(10): 1143-1152, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352880
5.
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Lancet Infect Dis
; 23(9): 1020-1030, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37216958
6.
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Lancet Respir Med
; 11(8): 698-708, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209700
7.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med
; 11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
8.
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Lancet Reg Health West Pac
; : 100829, 2023 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360864
Resultados
1 -
8
de 8
1
Próxima >
>>